Skip to main content
Premium Trial:

Request an Annual Quote

Pronota Raises $4.9M to Support Protein Biomarker Validation Studies; Appoints New CEO, Board Member

Premium

Belgian protein biomarker firm Pronota has raised €3.7 million ($4.9 million) a Series C financing round that it will use to complete protein biomarker validation studies for its pre-eclampsia, ovarian cancer, sepsis, and cardio-renal programs.

Participants in the round included LSP, Gimv, Biotech Fund Flanders, KBC Private Equity, Johnson & Johnson Development Corporation, VIB, MP Healthcare and MedSciences Capital, and a company founder.

Pronota's biomarker system consists of its discovery platform Masstermind and verification platform Massterclass. According to the company, the Masstermind system streamlines biomarker development by selecting for analysis only the N-terminal tryptic peptides of each protein, thereby reducing sample complexity. The Massterclass verification platform then uses multiple-reaction monitoring mass spectrometry to do targeted analysis of putative biomarkers.

Pronota also announced that Nick McCooke is stepping down as CEO and member of the company's board and will be replaced by Katleen Verleysen, formerly Pronota's chief operating officer. Board member John Berriman is also leaving. He will be replaced by Rudy Dekeyser, managing director of VIB.

With the close of this round, Pronota has now raised €26.1 million since it began fundraising with its Series A round in 2006.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.